Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price was up 10.4% on Wednesday . The stock traded as high as C$11.15 and last traded at C$11.15. 2,138 shares changed hands during mid-day trading, an increase of 79% from the average session volume of 1,194 shares. The stock had previously closed at C$10.10.
Devonian Health Group Price Performance
The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The company has a 50 day simple moving average of C$8.73 and a 200-day simple moving average of C$10.68. The stock has a market cap of C$31.01 million, a price-to-earnings ratio of -4.96 and a beta of 0.42.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
